Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials
复制标题
DOI：
10.1016/j.eururo.2005.12.031
复制
发表时间：
2006-03-01
期刊：
影响因子：
23.4
通讯作者：
Kurth, K
中科院分区：
文献类型：
--
作者：
Sylvester, RJ;van der Meijden, APM;Kurth, K
目的：提供表格，使泌尿科医生能够轻松计算浅表性膀胱癌患者经尿道电切术后的短期和长期复发和进展风险。方法：对2596例浅表性膀胱癌患者的个体数据进行综合分析，这些患者包括在7项欧洲癌症研究和治疗组织试验中。一个简单的评分系统是基于六个临床和病理因素：肿瘤数量，肿瘤大小，以前的复发率，T分类，原位癌，和等级。1年时复发和进展的概率范围分别为15%至61%和1%至17%。5年时，复发和进展的概率范围为31%~ 78%和小于1%~ 45%。结论：根据这些概率，泌尿科医生可以与患者讨论不同的选择，以确定最合适的治疗和随访频率。(c)2006 Elsevier B. V.保留所有权利。
Objectives: To provide tables that allow urologists to easily calculate a superficial bladder cancer patient's short- and long-term risks of recurrence and progression after transurethral resection.Methods: A combined analysis was carried out of individual patient data from 2596 superficial bladder cancer patients included in seven European Organization for Research and Treatment of Cancer trials.Results: A simple scoring system was derived based on six clinical and pathological factors: number of tumors, tumor size, prior recurrence rate, T category, carcinoma in situ, and grade. The probabilities of recurrence and progression at one year ranged from 15% to 61% and from less than 1% to 17%, respectively. At five years, the probabilities of recurrence and progression ranged from 31% to 78% and from less than 1% to 45%.Conclusions: With these probabilities, the urologist can discuss the different options with the patient to determine the most appropriate treatment and frequency of follow-up. (c) 2006 Elsevier B.V. All rights reserved.